A Study to Evaluate the Safety and Effectiveness of Endoluminal Clinical Treatment of Gastroesophageal Reflux Disease

Overview

About this study

The purpose of this study is to demonstrate the safety and effiectiveness of Aluvra for the treatment of GERD.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Hstory of heartburn-like pain, regurgitation, or both prior to the initiation of proton pump inhibitor (PPIs) therapy.
  • History of GERD symptoms of at least six months despite continuous PPIs.
  • GERD-HRQL score ≥15 after discontinuing PPI therapy.
  • GERD-HRQL score improvement of at least 6 points while on PPIs, with at least 4-point improvement in heartburn subscore.
  • A minimum GERD-HRQL score while on PPIs of 2.
  • Pathologic acid exposure time, a baseline pH <4.0 for ≥ 5.3% of time during a 48-hour evaluation period.
  • Twenty two years of age or older.
  • Life expectancy of at least two years.
  • Willing and able to return to the clinic or hospital for all evaluation procedures scheduled throughout the course of this study.
  • Is capable of understanding clinical study procedures and giving informed consent.

Exclusion Criteria: 

  • Unable to tolerate an endoscopic procedure.
  • Presence of esophageal or gastric varices.
  • Presence of erosive esophagitis (LA Classification of C or D).
  • Presence of a hiatal hernia > 2 cm.
  • Presence of Barrett's esophagus.
  • Presence of esophageal motility disorder.
  • History of or known esophageal stricture or gross esophageal anatomic abnormalities.
  • Symptoms of dysphagia more than once per week within the last six months.
  • Obesity (BMI ≥ 35).
  • Gastric or esophageal cancer undergoing active treatment. 
  • Received radiation therapy to the esophagus and has fibrosis of the tissue at the likely injection sites. 
  • Had an ablation procedure in the lower esophageal sphincter area. 
  • Has a condition that could lead to significant postoperative complications, including current infection, anticoagulant use, uncontrolled diabetes or autoimmune disorder.
  • Enrolled in a concurrent clinical trial.
  • Inability to comply with study protocol due to a chronic disease, psychiatric illness, alcoholism, drug abuse, or geographic distance (as determined by investigator). 
  • Pregnant and/or given birth in the previous twelve months or who plan to become pregnant in the next twelve months Prior gastric or GERD surgery.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Brian Lacy, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20453742

Mayo Clinic Footer